{"created":"2023-05-15T14:46:59.589353+00:00","id":10672,"links":{},"metadata":{"_buckets":{"deposit":"511cf682-f02a-43d5-aa50-6875102d27cb"},"_deposit":{"created_by":11,"id":"10672","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"10672"},"status":"published"},"_oai":{"id":"oai:ksu.repo.nii.ac.jp:00010672","sets":["14:226:1054"]},"author_link":["19368","22665","22666","6251"],"control_number":"10672","item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-07-30","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"116","bibliographicPageStart":"101","bibliographicVolumeNumber":"16","bibliographic_titles":[{"bibliographic_title":"京都産業大学総合学術研究所所報"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"食道がん患者臨床検体の免疫組織染色により，線維芽細胞増殖因子受容体3 の選択的スプライシングアイソフォーム（FGFR3IIIc）の発現が食道がん組織において上昇することを明らかにした。FGFR3IIIc のがん部位における発現比（がん部位/ 正常粘膜部位）と各患者の臨床情報を比較したところ，発現比の高いがん患者ほど，全生存期間が短くなることを見出した。大腸がん細胞Caco2 を用いて，FGFR3IIIc の発現をsiRNA でノックダウンすると細胞増殖能と浸潤能が阻害され，レンチウイルスにより発現を回復すると増殖能と浸潤能が上昇した。さらに，FGFR3IIIc の発現をノックダウンするとフルオロウラシルに対する抗がん剤のIC50 値が低くなり27.7 μM となったが，FGFR3IIIc を再び発現させるとIC50 値が1000 μM 以上になった。FGFR3IIIc の発現をノックダウンすると下流シグナル伝達経路のAkt，MAPK，PLCγ の活性化を阻害し，FGFR3IIIc の発現を回復すると，これらのタンパク質が再び活性化したことから，増殖能，浸潤能，抗がん剤耐性の獲得にFGFR3IIIc の下流シグナル伝達経路が関わっていることが示唆された。次に，消化器系がんの患者検体から得られたがん組織を用いてオルガノイド培養系を確立し，FGFR3IIIc が消化器系がん患者の治療予測マーカーとなりうるか，治療の分子標的として有用であるかを検討し，FGFR3IIIc シグナル制御による個別化医療への応用を目指す。","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"京都産業大学総合学術研究所"}]},"item_10002_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA11879037","subitem_source_identifier_type":"NCID"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1348-8465","subitem_source_identifier_type":"PISSN"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"瀬尾, 美鈴","creatorNameLang":"ja"},{"creatorName":"セオ, ミスズ","creatorNameLang":"ja-Kana"},{"creatorName":"SEO, Misuzu","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"福光, 一生","creatorNameLang":"ja"},{"creatorName":"フクミツ, カズキ","creatorNameLang":"ja-Kana"},{"creatorName":"FUKUMITSU, Kazuki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"上田, 修吾","creatorNameLang":"ja"},{"creatorName":"ウエダ, シュウゴ","creatorNameLang":"ja-Kana"},{"creatorName":"UEDA, Shugo","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"上野, 信洋","creatorNameLang":"ja"},{"creatorName":"ウエノ, ノブヒロ","creatorNameLang":"ja-Kana"},{"creatorName":"UENO, Nobuhiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-08-25"}],"displaytype":"detail","filename":"KSUSGKS_16_101.pdf","filesize":[{"value":"2.5 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KSUSGKS_16_101.pdf","url":"https://ksu.repo.nii.ac.jp/record/10672/files/KSUSGKS_16_101.pdf"},"version_id":"eb3966fa-3bdd-401d-8441-b0c71425f976"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"線維芽細胞増殖因子受容体3IIIc","subitem_subject_scheme":"Other"},{"subitem_subject":"食道がん","subitem_subject_scheme":"Other"},{"subitem_subject":"大腸がん","subitem_subject_scheme":"Other"},{"subitem_subject":"抗がん剤耐性","subitem_subject_scheme":"Other"},{"subitem_subject":"患者由来がんオルガノイド","subitem_subject_scheme":"Other"},{"subitem_subject":"Fibroblast growth factor receptor 3IIIc","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Esophageal cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Colorectal cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Drugresistance","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Patient-derived cancer organoid","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"消化器系がんに発現する線維芽細胞増殖因子受容体3IIIc のがん悪性化メカニズムの解析と個別化医療への応用","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"消化器系がんに発現する線維芽細胞増殖因子受容体3IIIc のがん悪性化メカニズムの解析と個別化医療への応用","subitem_title_language":"ja"},{"subitem_title":"Analysis of molecular mechanisms by Fibroblast Growth Factor Receptor 3IIIc in malignant progression in digestive cancer cells and application of cancer organoid model for personalized therapy.","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"11","path":["1054"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-08-25"},"publish_date":"2021-08-25","publish_status":"0","recid":"10672","relation_version_is_last":true,"title":["消化器系がんに発現する線維芽細胞増殖因子受容体3IIIc のがん悪性化メカニズムの解析と個別化医療への応用"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-07-14T05:35:31.247208+00:00"}